Learning Objectives:

1. Compare the REDUCE-IT and STRENGTH trials.
2. Discuss the role of Lp(a) and CV disease.
3. Understand the causal role of inflammation in ASCVD and potential therapies.

Session date: 
04/09/2021 - 12:00pm to 1:00pm CDT
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Michael Davidson, MD